Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis

NCT05645627 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.

NCT NCT05645627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05645627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
February 10, 2023
Completion date
August 1, 2024
Enrollment
500 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis